Equity Research Software - Infrastructure

Should You Buy Cellebrite DI Ltd. Stock in 2026?

By CirclFi Research Team · · Updated · 1/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Cellebrite DI Ltd. (CLBT) sits in the bottom tier of our quality coverage with a score of 3.0/10. While a weak quality score suggests operational challenges, our valuation models assess if the market has over-discounted the stock at $11.25.

The short answer: 1 of 1 CirclFi valuation models project upside for Cellebrite DI Ltd. (CLBT) at $11.25 — the model consensus leans bullish, with a Quality Score of 3.0/10 and Value-Trap risk of 0/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 1 of 1 models see upside — majority bullish
  • Quality Score: 3.0/10 — Very Weak — significant concerns
  • Value Trap Risk: 0/100 — Minimal — healthy fundamentals
  • Fair Value Range: $17.27 – $17.27 (0% spread)

Bullish Models

1 / 1

Bearish Models

0 / 1

Quality Score

3.0 /10

Very Weak — significant concerns

Value Trap Risk

0 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

1 /13
Active Models

Avg. confidence: 25%

What Is the Investment Case for Cellebrite DI Ltd. (CLBT) in 2026?

What Is the Bull Case vs the Bear Case for Cellebrite DI Ltd. (CLBT)?

Bull case versus bear case for Cellebrite DI Ltd. (CLBT) at $11.25, derived from 1 active CirclFi valuation models on 2026-09-15.
Bull case — $17.27 target (+53.5%) Bear case
According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $11.25 and the median fair value of $17.27 implies +53.5% upside potential. No active model flags significant downside for CLBT. The low Value Trap score paints a constructive picture.
According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $17.27 (+53.5%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
Industry tailwind: enterprise adoption could provide meaningful support for Cellebrite DI Ltd.'s revenue and margin trajectory in the Software - Infrastructure space.

How Does CLBT Compare to Its Software - Infrastructure Peers?

QMLS QumulusAI, Inc.
3.0
SUPX SuperX AI Technology
3.0
GYGY Game Your Game, Inc.
3.1
RDWR Radware Ltd.
2.9
IPSI Innovative Payment S
3.2
RZLV Rezolve AI PLC
2.7
FLYW Flywire Corporation
8.3
SAIL SailPoint, Inc.
6.4

Valuation data pages: QMLS · SUPX · GYGY · RDWR · IPSI · RZLV · FLYW · SAIL · OLB · FTNT · QLYS

See full Software - Infrastructure rankings →

Which Other Stocks Score Like CLBT on Quality?

Closest companies to CLBT’s Quality of Company score of 3.0/10, across all industries.

Why Do CirclFi’s 1 Models Disagree on CLBT?

Spread

0%

Fair Value Range

$17.27 – $17.27

A tight 0% spread suggests meaningful convergence, strengthening conviction in the composite estimate.

Most Bullish

Regime Cross

$17.27 (+53.5%)

Most Bearish

Regime Cross

$17.27 (+53.5%)

What Are the Biggest Risks of Buying CLBT Stock?

Weak Fundamentals

QOC 3.0/10 signals below-average quality.

Macro/Sector Risk

Software - Infrastructure headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View CLBT Data Page →

So Is Cellebrite DI Ltd. (CLBT) Worth Buying in 2026?

Cellebrite DI Ltd. at $11.25 presents what our engine identifies as a high-conviction opportunity: 1 of 1 models see upside, quality stands at 3.0/10, and the median fair value of $17.27 implies +53.5% return potential. Investors should verify this thesis against their own risk parameters and time horizon.

These are quantitative model outputs, not investment recommendations. Cellebrite DI Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About CLBT Stock?

Should I buy CLBT stock right now?

Based on CirclFi's multi-model analysis, 1 of 1 models see upside for CLBT at $11.25. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 3.0/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Cellebrite DI Ltd.?

Key risks include: a below-average Quality Score of 3.0/10, indicating fundamental weakness; limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Software - Infrastructure companies. Always diversify and consult a financial advisor.

How does CLBT compare to its competitors?

Among Software - Infrastructure peers, CLBT holds a Quality Score of 3.0/10. Comparable companies include QMLS (QOC 3.0), SUPX (QOC 3.0), GYGY (QOC 3.1). The relative ranking helps investors identify whether CLBT offers better fundamental quality than alternatives in the same sector.

Is CLBT a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CLBT's Quality Score of 3.0/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy CLBT at?

CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $17.27 to $17.27. At $11.25, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for CLBT.

View CLBT Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →